Form 4: Dianthus Therapeutics, Inc. /DE/ CEO Sells Shares
Insider Transaction (Form 4)
Marino Garcia, CEO AND PRESIDENT and a Director of Dianthus Therapeutics, Inc. /DE/, sold 166,000 shares of common stock on August 7, 2026.
Summary
- Option exercise/conversion: acquired 40,000 Common Stock at $8.44 ($337,600) on August 7, 2026; holds 105,292 after (Direct).
- Option exercise/conversion: acquired 126,000 Common Stock at $8.44 ($1,063,440) on August 7, 2026; holds 231,292 after (Direct).
- Open-market sale: disposed of 10,384 Common Stock at $107.49 ($1,116,176) on August 7, 2026; holds 220,908 after (Direct).
- Open-market sale: disposed of 23,907 Common Stock at $108.05 ($2,583,151) on August 7, 2026; holds 197,001 after (Direct).
- Open-market sale: disposed of 2,373 Common Stock at $109.10 ($258,894) on August 7, 2026; holds 194,628 after (Direct).
- Open-market sale: disposed of 2,536 Common Stock at $110.02 ($279,011) on August 7, 2026; holds 192,092 after (Direct).
- Open-market sale: disposed of 800 Common Stock at $110.76 ($88,608) on August 7, 2026; holds 191,292 after (Direct).
- Open-market sale: disposed of 104,091 Common Stock at $107.96 ($11,237,664) on August 7, 2026; holds 87,102 after (Direct).
- Open-market sale: disposed of 21,909 Common Stock at $108.72 ($2,381,946) on August 7, 2026; holds 65,292 after (Direct).
- Option exercise/conversion: disposed of 40,000 Stock Option (Right to Buy) on August 7, 2026; holds 286,004 after (Direct).
- Option exercise/conversion: disposed of 126,000 Stock Option (Right to Buy) on August 7, 2026; holds 160,004 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $17,945,451 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Marino Garcia — Director, Officer (CEO AND PRESIDENT)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-07 | Option exercise/conversion | Common Stock | 40,000 | $8 | $337.6K | 105,292 |
| 2026-08-07 | Option exercise/conversion | Common Stock | 126,000 | $8 | $1.1M | 231,292 |
| 2026-08-07 | Open-market sale | Common Stock | 10,384 | $107 | $1.1M | 220,908 |
| 2026-08-07 | Open-market sale | Common Stock | 23,907 | $108 | $2.6M | 197,001 |
| 2026-08-07 | Open-market sale | Common Stock | 2,373 | $109 | $258.9K | 194,628 |
| 2026-08-07 | Open-market sale | Common Stock | 2,536 | $110 | $279.0K | 192,092 |
| 2026-08-07 | Open-market sale | Common Stock | 800 | $111 | $88.6K | 191,292 |
| 2026-08-07 | Open-market sale | Common Stock | 104,091 | $108 | $11.2M | 87,102 |
| 2026-08-07 | Open-market sale | Common Stock | 21,909 | $109 | $2.4M | 65,292 |
| 2026-08-07 | Option exercise/conversion | Stock Option (Right to Buy) | 40,000 | — | — | 286,004 |
| 2026-08-07 | Option exercise/conversion | Stock Option (Right to Buy) | 126,000 | — | — | 160,004 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-07 | Option exercise/conversion (40,000 shares) |
| 2026-08-07 | Option exercise/conversion (126,000 shares) |
| 2026-08-07 | Open-market sale (10,384 shares) |
| 2026-08-07 | Open-market sale (23,907 shares) |
| 2026-08-07 | Open-market sale (2,373 shares) |
| 2026-08-07 | Open-market sale (2,536 shares) |
| 2026-08-07 | Open-market sale (800 shares) |
| 2026-08-07 | Open-market sale (104,091 shares) |
| 2026-08-07 | Open-market sale (21,909 shares) |
| 2026-08-07 | Option exercise/conversion (40,000 shares) |
| 2026-08-07 | Option exercise/conversion (126,000 shares) |
Keywords
insider transaction, Form 4, DNTH, Dianthus Therapeutics, Inc. /DE/, bearish, Marino Garcia
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.